An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

Melanoma is an extremely aggressive tumor and is considered to be an extremely
immunogenic tumor because compared to other cancers it usually presents a well …

Introduction With new systemic therapies demonstrating activity in melanoma brain
metastasis, most of the previously reported stereotactic radiosurgery (SRS) data are …

Purpose Prior statistical models attempted to identify risk factors for time to distant brain
failure (DBF) or time to salvage whole-brain radiation therapy (WBRT) to predict the benefit …

Background The effect of immunotherapy on brain metastasis patients remains incompletely
understood. Our goal was to evaluate its effect on survival, neurologic death, and patterns of …

Brain metastases account for considerable morbidity and mortality in patients with cancer.
Despite increasing prevalence, limited therapeutic options exist. Recent advances in our …

OBJECT BRAF inhibitors improve progression-free and overall survival in patients with
metastatic melanoma. Brain metastases are common, and stereotactic radiosurgery (SRS) …

Background. In this study we attempted to discern the factors predictive of neurologic death
in patients with brain metastasis treated with upfront stereotactic radiosurgery (SRS) without …

The aim of this study was to evaluate the impact of BRAF inhibitors on survival outcomes in
patients receiving stereotactic radiosurgery (SRS) for melanoma brain metastases. We …

Purpose To estimate the hazard for neurologic (central nervous system, CNS) and
nonneurologic (non-CNS) death associated with patient, treatment, and systemic disease …